Incyte Corporation Overview
Pro stress-test →Incyte is a global biopharmaceutical company with three core franchises in Hematology, Oncology and Inflammation and Autoimmunity. The company achieved a milestone of crossing the $5 billion annual revenue mark, driven primarily by its blockbuster JAK inhibitor Jakafi and emerging dermatology franchise Opzelura.
Strategic Profile
Pro stress-test →Incyte is expanding into dermatology via Opzelura while facing a looming patent cliff of its core franchise in 2028. The company aims to grow its core business (excluding Jakafi) to $3–4 billion by 2030. New CEO Bill Meury is betting on a commercial turnaround with institutional investors including Vanguard and BlackRock holding major positions.
Competitive Landscape
Pro stress-test →Incyte no longer enjoys a monopoly in the JAK inhibitor space with GSK's Ojjaara competing in hematology and AbbVie/Lilly products competing in dermatology. In Oncology, the landscape is shifting toward combination therapies where larger peers like Bristol Myers Squibb are increasingly aggressive.
Industry Context
Incyte Corporation operates in Biopharmaceuticals.
Key facts
Founded: 2002 · Headquarters: Wilmington, Delaware · Revenue: $5.14B · Market cap: $21.4B